Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus

The Japanese biosimilar market is on a roll. The volume-based shares of Enbrel (etanercept) and Forteo (teriparatide) biosimilars in their respective markets have already reached 40%, while Herceptin (trastuzumab) follow-ons have far exceeded the 50% mark. Coupled with new reimbursement...read more